Vericel Expects Record MACI Sales to End 2021

Vericel reported 3Q21 orthopedic sales for MACI of $23.9 million, -2% vs. 3Q20. The declines stemmed from a mixture of normal seasonality, patient-driven delays and surging COVID cases during the quarter. While the third quarter is generally slower for Vericel, July brought uncharacteristically high deferrals as economies reopened and...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.

Contact Us